{'fraction_non_alphanumeric': 0.02395964691046658, 'fraction_numerical': 0.008827238335435058, 'mean_word_length': 5.728813559322034, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
CB1 cannabinoid receptor ligands augment the antidepressant‐like activity of biometals (magnesium and zinc) in the behavioural tests

During the last few decades, endocannabinoid system has emerged as a novel possible target for antidepressant treatment. Although the medical literature provides information on the mood‐changing effects of CB1 ligands, little is known about the possible interaction between the simultaneous activation or inhibition of the CB1 receptor and administration of other agents that possess antidepressant potential. The main goal of our study was to evaluate the influence of the CB1 cannabinoid receptor ligands (oleamide – an endogenous agonist and AM251 – an inverse agonist/antagonist) on the antidepressant‐like activity of biometals (i.e. magnesium and zinc).